# TScan Therapeutics (TCRX) — News

TCRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tcrx/news

## Recent headlines

- [Tscan Therapeutics, Inc.: H.C. Wainwright cuts to neutral from buy](https://www.ainvest.com/news/tscan-therapeutics-wainwright-cuts-neutral-buy-2609) — AInvest Wire, Sep 8, 2026
  H.C. Wainwright & Co. has revised its rating for Tscan Therapeutics, Inc. (NASDAQ: TSCR) from "Buy" to "Neutral," reflecting a reassessment of the company's near-term prospects and market dynamics. The downgrade comes amid ongoing clinical development for Tscan's pipeline, which includes TTI-100, a…
- [Tscan Therapeutics Inc: Wedbush cuts to neutral from outperform; cuts target price to $1 from $5](https://www.ainvest.com/news/tscan-therapeutics-wedbush-cuts-neutral-outperform-cuts-target-price-1-5-2609) — AInvest Wire, Sep 2, 2026
  TScan Therapeutics Inc. (TCRX) has seen recent shifts in analyst sentiment, with Wedbush downgrading its recommendation to "neutral" from "outperform" and reducing its price target to $1 from $5. This adjustment reflects a reassessment of the company's near-term prospects amid ongoing financial…
- [Tscan pauses phase 3 alloha-2 trial](https://www.ainvest.com/news/tscan-pauses-phase-3-alloha-2-trial-2609) — AInvest Wire, Sep 2, 2026
- [Tscan Therapeutics announces strategic reorganization](https://www.ainvest.com/news/tscan-therapeutics-announces-strategic-reorganization-2609) — AInvest Wire, Sep 2, 2026
- [Tscan Therapeutics - Pauses enrollment in phase 3 alloha-2 study of TSC-101 due to insufficient capital](https://www.ainvest.com/news/tscan-therapeutics-pauses-enrollment-phase-3-alloha-2-study-tsc-101-due-insufficient-capital-2609) — AInvest Wire, Sep 2, 2026
  TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced the temporary pause of enrollment in its Phase 3 ALLOHA-2™ trial of TSC-101, a T cell receptor (TCR)-engineered T cell therapy candidate for the treatment of residual disease following allogeneic hematopoietic cell transplantation (allo-HCT) in…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).